Aminopeptidase N (CD13) as a target for cancer chemotherapy
- PMID: 21205077
- PMCID: PMC7188354
- DOI: 10.1111/j.1349-7006.2010.01826.x
Aminopeptidase N (CD13) as a target for cancer chemotherapy
Abstract
The enzyme aminopeptidase N (APN, also known as CD13) is a Zn(2+) dependent membrane-bound ectopeptidase that degrades preferentially proteins and peptides with a N-terminal neutral amino acid. Aminopeptidase N has been associated with the growth of different human cancers and suggested as a suitable target for anti-cancerous therapy. Different approaches have been used to develop new drugs directed to this target, including enzyme inhibitors as well as APN-targeted carrier constructs. This review discusses the prevalence and possible function of APN in malignant diseases, mainly solid tumors, as well as its "drugability" evaluated in preclinical in vivo models, and also provides a brief overview of current clinical trials focused on APN.
© 2011 Japanese Cancer Association.
References
-
- Dubowchik GM, Walker MA. Receptor‐mediated and enzyme‐dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 1999; 83: 67–123. - PubMed
-
- Taylor A. Aminopeptidases: towards a mechanism of action. Trends Biochem Sci 1993; 18: 167–71. - PubMed
-
- Taylor A. Aminopeptidases: structure and function. FASEB J 1993; 7: 290–8. - PubMed
-
- Luan Y, Xu W. The structure and main functions of aminopeptidase N. Curr Med Chem 2007; 14: 639–47. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
